Wedge SR - Search Results

1

The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.

Shannon AM, Telfer BA, Smith PD, Babur M, Logie A, Wilkinson RW, Debray C, Stratford IJ, Williams KJ, Wedge SR. Shannon AM, et al. Among authors: wedge sr. Clin Cancer Res. 2009 Nov 1;15(21):6619-29. doi: 10.1158/1078-0432.CCR-08-2958. Epub 2009 Oct 20. Clin Cancer Res. 2009. PMID: 19843666 Free article.

2

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF. Wedge SR, et al. Cancer Res. 2000 Feb 15;60(4):970-5. Cancer Res. 2000. PMID: 10706112

3

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

Williams KJ, Telfer BA, Stratford IJ, Wedge SR. Williams KJ, et al. Among authors: wedge sr. Br J Cancer. 2002 Apr 8;86(7):1157-61. doi: 10.1038/sj.bjc.6600182. Br J Cancer. 2002. PMID: 11953865 Free PMC article.

4

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF. Wedge SR, et al. Cancer Res. 2002 Aug 15;62(16):4645-55. Cancer Res. 2002. PMID: 12183421

5

ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.

Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR. Williams KJ, et al. Among authors: wedge sr. Clin Cancer Res. 2004 Dec 15;10(24):8587-93. doi: 10.1158/1078-0432.CCR-04-1147. Clin Cancer Res. 2004. PMID: 15623642

6

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ. Wedge SR, et al. Cancer Res. 2005 May 15;65(10):4389-400. doi: 10.1158/0008-5472.CAN-04-4409. Cancer Res. 2005. PMID: 15899831

7

Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.

Jung FH, Pasquet G, Lambert-van der Brempt C, Lohmann JJ, Warin N, Renaud F, Germain H, De Savi C, Roberts N, Johnson T, Dousson C, Hill GB, Mortlock AA, Heron N, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Green S, Brown E, Thompson K, Brightwell S. Jung FH, et al. Among authors: wedge sr. J Med Chem. 2006 Feb 9;49(3):955-70. doi: 10.1021/jm050786h. J Med Chem. 2006. PMID: 16451062

8

Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.

Goodlad RA, Ryan AJ, Wedge SR, Pyrah IT, Alferez D, Poulsom R, Smith NR, Mandir N, Watkins AJ, Wilkinson RW. Goodlad RA, et al. Among authors: wedge sr. Carcinogenesis. 2006 Oct;27(10):2133-9. doi: 10.1093/carcin/bgl113. Epub 2006 Jun 16. Carcinogenesis. 2006. PMID: 16782971

9

Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.

Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Williams KJ, et al. Among authors: wedge sr. Mol Cancer Ther. 2007 Feb;6(2):599-606. doi: 10.1158/1535-7163.MCT-06-0508. Mol Cancer Ther. 2007. PMID: 17308057 Free article.

10

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S. Mortlock AA, et al. Among authors: wedge sr. J Med Chem. 2007 May 3;50(9):2213-24. doi: 10.1021/jm061335f. Epub 2007 Mar 21. J Med Chem. 2007. PMID: 17373783

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

92 results

Search Page

Filters